Navigation Links
China Biologic Products Begins Annual Maintenance of its Production Facilities
Date:8/1/2008

TAIAN CITY, Shandong, China, Aug. 1 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("CBP," or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that the Company began its annual maintenance of its production facilities on July 25, 2008.

The maintenance period will last for one month, during which time production at the manufacturing facilities will be suspended. During the required maintenance period, the Company will conduct any required major maintenance of its production equipment to ensure the efficiency and safety of subsequent production. The Company will also take advantage of the maintenance period to train its staff, and allow them to take proper vacation time as required by Chinese labor laws.

In addition, since the manufacturing process known as Compression and Filtration in Cold Ethanol Fractionation for human plasma albumin and immunoglobulin related products requires constant low temperature, CBP has carefully planned its maintenance period to fall during the hottest days of summer in order to conserve energy and curtail expenses related to recent increases in fuel costs.

CBP has sufficient product inventories on hand to meet market demand during the maintenance period. In addition, operation of the Company's plasma collection stations will continue as usual to ensure that the manufacturing facilities can resume their normal operations at the end of the maintenance period.

"We chose to conduct the maintenance period in the summer when production costs are usually at the highest," said Mr. Chao Ming Zhao, the Company's CEO. "The annual routine maintenance of our manufacturing facilities is not expected to affect our sales revenue in the third quarter, as we have stocked sufficient inventories to meet our projected demand."

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the impact of the maintenance on the Company's third quarter revenues; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Company Contact:

Mr. Y. Tristan Kuo

CFO

China Biologic Products, Inc.

Tel: +86-538-6202206

Email: IR@chinabiologic.com

Web: http://www.chinabiologic.com

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Investor Relations

Tel: +1-646-213-1915 (NY office)

Email: crocker.coulson@ccgir.com

Web: http://www.ccgir.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Pharma Holdings, Inc. to Host Second Quarter 2008 Earnings Conference Call at 10 a.m. EDT Wednesday August 6, 2008
2. China Biologic Products Establishes Audit Committee and Appoints Three New Independent Directors to Board of Directors
3. Global Stem Cell Forum in China Showcases Cutting Edge Research, Focuses on New Findings for iPS Cells
4. China Medical Technologies Adjusts Conversion Rate of Convertible Notes
5. China-Biotics, Inc. Files Application for Nasdaq Listing
6. China Biologic Products Honored with the Advanced Technology Certification for Foreign-Funded Enterprises
7. China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008
8. China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results
9. WuXi PharmaTech (NYSE: WX) Named the Most Innovative Company in China and CEO Dr. Li the Most Innovative Leader of Chinese Enterprises
10. China Biologic Products Begins Operation of its Newly Constructed Plasma Collection Station in Qi He County, Shandong Province
11. China Agritech to Export Products to Egypt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  Renova™ Therapeutics, a biotechnology ... failure and type 2 diabetes, announced that it ... adeno-associated virus (AAV) vector developed in the laboratory ... at Stanford University. The company plans to use ... therapy product pipeline. "Early research ...
(Date:12/8/2016)... CARDIFF, UK (PRWEB) , ... December 08, 2016 ... ... high precision light to control cells — optogenetics — is key to exciting ... state of the art, spatially patterned light projected via free-space optics stimulates small, ...
(Date:12/8/2016)... OXFORD, England , December 8, 2016 /PRNewswire/ ... (OGT), das Unternehmen für Molekulargenetik, erweitert seine Palette ... SureSeq myPanel™ NGS Custom FH Panels, das ein ... Hypercholesterinämie (FH) ermöglicht. Das Panel bietet eine Erkennung ... Number Variations (CNV) mit einem einzigen kleinen Panel ...
(Date:12/8/2016)... , Dec. 8, 2016  Anaconda BioMed S.L., a ... of the next generation neuro-thrombectomy system for the treatment ... Tudor G. Jovin, MD to join its Scientific Advisory ... a strategic network of scientific and clinical experts to ... of the ANCD BRAIN ® to its clinical ...
Breaking Biology Technology:
(Date:11/22/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that the company has ... Sciences Awards as "Most Outstanding in eClinical Solutions" ... of recognition and growth for MedNet, which has effectively ... iMedNet ™ , MedNet,s flagship eClinical ...
(Date:11/17/2016)... , Nov. 17, 2016 Global Market Watch: ... Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market is to ... for Private Biobanks shows the highest Compounded Annual Growth Rate ... region during the analysis period 2014-2020. North ... of 9.95% followed by Europe at ...
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
Breaking Biology News(10 mins):